- Home
- PLG vs IMMP Comparison
PLG vs IMMP Comparison
Compare PLG & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLG
- IMMP
- Stock Information
- Founded
- PLG 2000
- IMMP 1987
- Country
- PLG Canada
- IMMP Australia
- Employees
- PLG N/A
- IMMP N/A
- Industry
- PLG
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- PLG
- IMMP Health Care
- Exchange
- PLG Nasdaq
- IMMP Nasdaq
- Market Cap
- PLG 217.6M
- IMMP 251.8M
- IPO Year
- PLG N/A
- IMMP N/A
- Fundamental
- Price
- PLG $2.78
- IMMP $2.08
- Analyst Decision
- PLG
- IMMP Buy
- Analyst Count
- PLG 0
- IMMP 1
- Target Price
- PLG N/A
- IMMP $7.00
- AVG Volume (30 Days)
- PLG 3.3M
- IMMP 93.3K
- Earning Date
- PLG 11-25-2025
- IMMP 10-10-2025
- Dividend Yield
- PLG N/A
- IMMP N/A
- EPS Growth
- PLG N/A
- IMMP N/A
- EPS
- PLG N/A
- IMMP N/A
- Revenue
- PLG N/A
- IMMP $3,306,742.00
- Revenue This Year
- PLG N/A
- IMMP $16.82
- Revenue Next Year
- PLG N/A
- IMMP N/A
- P/E Ratio
- PLG N/A
- IMMP N/A
- Revenue Growth
- PLG N/A
- IMMP 31.28
- 52 Week Low
- PLG $0.99
- IMMP $1.32
- 52 Week High
- PLG $3.07
- IMMP $2.71
- Technical
- Relative Strength Index (RSI)
- PLG 78.59
- IMMP 72.79
- Support Level
- PLG $2.43
- IMMP $1.75
- Resistance Level
- PLG $3.07
- IMMP $1.89
- Average True Range (ATR)
- PLG 0.24
- IMMP 0.08
- MACD
- PLG 0.05
- IMMP 0.04
- Stochastic Oscillator
- PLG 79.63
- IMMP 93.62
About PLG Platinum Group Metals Ltd. (Canada)
Platinum Group Metals Ltd is the operator of the Waterberg Project, a bulk underground PGM deposit located in South Africa. Waterberg was discovered by Platinum Group and is being jointly developed with Implats, the Japan Oil, Gas and Metals National Corporation (JOGMEC) and Hanwa Co. Ltd. Waterberg has the potential to be a large-scale, low-cost producer of palladium, platinum, rhodium, and gold. Geographically, it operates in Canada and South Africa.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.